Published in Immunotargets Ther on September 18, 2013
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc (2008) 8.94
Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.90
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol (2011) 2.57
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol (2006) 2.27
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol (2005) 2.25
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One (2007) 1.86
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther (2011) 1.66
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol (2008) 1.47
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med (2003) 1.27
Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer (1999) 1.23
Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg (2004) 1.17
Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol (2012) 1.17
A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis. Glycobiology (1998) 1.10
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol (1998) 1.06
Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Ann Oncol (2011) 1.03
Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther (2008) 1.02
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer (2004) 0.99
Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol (1995) 0.98
Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin (2007) 0.98
Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother (1991) (1992) 0.96
What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann Oncol (2012) 0.93
Murine tumor antigens: is it worth the search? Curr Opin Immunol (1996) 0.91
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer (1992) 0.89
Bacteria and cancer--antagonisms and benefits. Cancer Surv (1989) 0.88
Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS). Cancer (1979) 0.88
Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. Clin Cancer Res (1999) 0.85
Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Res (1986) 0.84
Thymosin immunotherapy in patients with small cell carcinoma of the lung: correlation of in vitro studies with clinical course. Cancer (1979) 0.83
Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials. Crit Rev Oncol Hematol (2012) 0.83
Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin. Cancer Res (1979) 0.83
Lung cancer vaccines. Cancer J (2011) 0.82
BCG immunotherapy of lung cancer in a district oncology dispensary. I. Study of 860 patients with histologic diagnosis. Neoplasma (1982) 0.81
Combination chemoimmunotherapy for extensive non-oat cell lung cancer. Cancer Treat Rep (1978) 0.81
Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. J Clin Oncol (1985) 0.80
Active immunotherapy for non-small-cell lung cancer: moving toward a reality. Expert Rev Anticancer Ther (2011) 0.79